The United States authorized a new treatment against migraine that has the particularity of being administered through a nasal spray, announced this Friday the pharmaceutical giant Pfizer.
This treatment, which will be marketed under the name Zavzpret, received authorization from the US Food and Drug Administration (FDA) for the treatment of severe migraine in adults.
In a large clinical trial, the results of which were published last month in the scientific journal Lancet Neurology, the drug demonstrated positive pain-relieving effects greater than placebo, sometimes as quickly as 15 minutes after a dose, according to Pfizer.
“One of the most important characteristics of an acute treatment option is how quickly it works,” said Kathleen Mullin of the New England Institute of Neurology and Headaches, quoted in the Pfizer statement.
“As a rapidly absorbed nasal spray, Zavzpret offers an alternative treatment option for those who need relief and are unable to take oral medications due to nausea or vomiting,” added.
Migraines can have a significant effect on daily life and They are usually accompanied, in addition to headaches, visual disturbances or intolerance to light.
Pfizer said the treatment It will be available in US pharmacies in July 2023.